investors

Press Releases

DateTitle and SummaryView
September 24, 2015
ICT-107 Phase 3 Trial on Track to Begin in Fourth Quarter
ImmunoCellular Therapeutics Awarded $19.9 Million Grant from California Institute for Regenerative Medicine (CIRM) to Fund ICT-107 Phase 3 Registration Program in Glioblastoma
September 22, 2015
Mr. Schlossberg and Mr. Lapointe Will Serve as Independent Members of the Board of Directors
ImmunoCellular Therapeutics Appoints Mark A. Schlossberg and Gregg A. Lapointe to its Board of Directors
August 21, 2015
LOS ANGELES , Aug. 21, 2015 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. (" ImmunoCellular ") (NYSE MKT: IMUC) today issued the following letter to shareholders. To Our Shareholders: As we work toward building a leading cancer immunotherapy company, the management and board of directors of
ImmunoCellular Therapeutics Issues Letter to Shareholders, Highlighting Progress on Advancing ICT-107 to Phase 3 Registrational Trial
August 13, 2015
LOS ANGELES , Aug. 13, 2015 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. (" ImmunoCellular ") (NYSE MKT: IMUC) announced today that it has reached agreement with the US Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for the phase 3 registrational trial of its cancer
ImmunoCellular Therapeutics Reaches Agreement with FDA on Special Protocol Assessment (SPA) for ICT-107 Phase 3 Registrational Trial in Glioblastoma
August 6, 2015
ICT-107 Phase 3 Registration Trial to Begin Late Third Quarter or Early Fourth Quarter 2015; Stem-to-T-cell Program Advancing
ImmunoCellular Therapeutics Announces Second Quarter 2015 Financial Results
July 23, 2015
LOS ANGELES , July 23, 2015 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. (" ImmunoCellular ") (NYSE MKT: IMUC) today announced that it plans to report financial results for the second quarter 2015 on Thursday, August 6, 2015 . The Company also plans to hold a conference call and webcast on
ImmunoCellular Therapeutics to Report Second Quarter 2015 Financial Results on August 6, 2015
July 6, 2015
LOS ANGELES , July 6, 2015 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. (" ImmunoCellular ") (NYSE MKT: IMUC) today announced the establishment of an agreement with Novella Clinical (Novella), to conduct the phase 3 registration trial of ICT-107 in patients with newly diagnosed glioblastoma.
ImmunoCellular Therapeutics Establishes Agreement with Novella Clinical to Conduct ICT-107 Phase 3 Registration Trial in Glioblastoma
June 29, 2015
LOS ANGELES , June 29, 2015 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. (" ImmunoCellular ") (NYSE MKT: IMUC) today announced that Andrew Gengos , Chief Executive Officer of ImmunoCellular , will present a corporate overview and business update at the Cantor Fitzgerald Inaugural Healthcare
ImmunoCellular Therapeutics to Present at Cantor Fitzgerald Inaugural Healthcare Conference on July 8th
June 22, 2015
LOS ANGELES , June 22, 2015 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. (" ImmunoCellular ") (NYSE MKT: IMUC) announced an agreement with Pure MHC, an Emergent Technologies portfolio company, for development of a novel assay for quality control that will be an important component of
ImmunoCellular Therapeutics Establishes Agreement with Pure MHC for Novel Quality Control Assay for ICT-107 Phase 3 Registrational Trial
June 15, 2015
LOS ANGELES , June 15, 2015 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. (" ImmunoCellular ") (NYSE MKT: IMUC) announced the selection of PCT, LLC , a subsidiary of Caladrius Biosciences, Inc. ("Caladrius") (NASDAQ:CLBS), as the US manufacturer for ImmunoCellular's ICT-107 phase 3
ImmunoCellular Therapeutics Enters into Manufacturing Agreement with PCT LLC, a Caladrius Company, for US Production of ICT-107 for Phase 3 Registration Trial
Copyright 2018 by Immunocellular Therapeutics, Ltd.
All Rights Reserved